{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.28","upperLimit":"96.24","value":"86.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Confirmed objective response rate (per RECIST 1.1 using Investigator assessments) is defined as the number (%) of subjects with at least 1 visit response of Completed Response (CR) or Partial Response (PR), where each CR or PR must be subsequently confirmed at least 4 weeks after the visit when the response was first observed with no evidence of progression between the initial and CR/PR confirmation visit.\n\nConfidence Interval is calculated using the exact Clopper-Pearson method.\n\nPer the protocol, the safety run-in treatment arms were combined and analyzed regardless of chemotherapy received for consistency with the randomized component.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes all participants in both Safety Run-In treatment arms: AZD9291 + Carboplatin + Pemetrexed and AZD9291 + Cisplatin + Pemetrexed","id":"OG000","title":"Overall Safety Run-In Participants"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set, includes all participants in the Safety Run-In Treatment Arms who received at least 1 dose of study treatment (osimertinib, cisplatin, carboplatin, or pemetrexed).","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Objective Response Rate (ORR) (Safety Run-In Treatment Arms Only)","type":"SECONDARY","unitOfMeasure":"Percent of Participants"}